The Journal of Allergy and Clinical Immunology
Volume 119, Issue 1 , Pages 192-198, January 2007

Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebo-controlled trial

  • Kaarina Kukkonen, MD

      Affiliations

    • From the Skin and Allergy Hospital, University of Helsinki
    • Corresponding Author InformationReprint requests: Kaarina Kukkonen, MD, Helsinki University Central Hospital, the Skin and Allergy Hospital, Meilahdentie 2, PO Box 160, 00029 HUCH Helsinki, Finland.
  • ,
  • Erkki Savilahti, MD, PhD

      Affiliations

    • Hospital for Children and Adolescents, University of Helsinki
  • ,
  • Tari Haahtela, MD, PhD

      Affiliations

    • From the Skin and Allergy Hospital, University of Helsinki
  • ,
  • Kaisu Juntunen-Backman, MD, PhD

      Affiliations

    • From the Skin and Allergy Hospital, University of Helsinki
  • ,
  • Riitta Korpela, PhD

      Affiliations

    • Institute of Biomedicine, Pharmacology, University of Helsinki
    • Valio Research and Development, Helsinki
  • ,
  • Tuija Poussa, MSc

      Affiliations

    • STAT-consulting, Tampere
  • ,
  • Tuula Tuure, PhD

      Affiliations

    • Valio Research and Development, Helsinki
  • ,
  • Mikael Kuitunen, MD, PhD

      Affiliations

    • From the Skin and Allergy Hospital, University of Helsinki

Received 9 June 2006; received in revised form 7 September 2006; accepted 11 September 2006. published online 27 October 2006.

Helsinki and Tampere, Finland

Background

The increase in allergic diseases is attributed to a relative lack of microbial stimulation of the infantile gut immune system. Probiotics, live health-promoting microbes, might offer such stimulation.

Objective

We studied the effect of a mixture of 4 probiotic bacterial strains along with prebiotic galacto-oligosaccharides in preventing allergic diseases.

Methods

We randomized 1223 pregnant women carrying high-risk children to use a probiotic preparation or a placebo for 2 to 4 weeks before delivery. Their infants received the same probiotics plus galacto-oligosaccharides (n = 461) or a placebo (n = 464) for 6 months. At 2 years, we evaluated the cumulative incidence of allergic diseases (food allergy, eczema, asthma, and allergic rhinitis) and IgE sensitization (positive skin prick test response or serum antigen-specific IgE level >0.7 kU/L). Fecal bacteria were analyzed during treatment and at age 2 years.

Results

Probiotic treatment compared with placebo showed no effect on the cumulative incidence of allergic diseases but tended to reduce IgE-associated (atopic) diseases (odds ratio [OR], 0.71; 95% CI, 0.50-1.00; P = .052). Probiotic treatment reduced eczema (OR, 0.74; 95% CI, 0.55-0.98; P = .035) and atopic eczema (OR, 0.66; 95% CI, 0.46-0.95; P = .025). Lactobacilli and bifidobacteria more frequently (P < .001) colonized the guts of supplemented infants.

Conclusion

Probiotic treatment showed no effect on the incidence of all allergic diseases by age 2 years but significantly prevented eczema and especially atopic eczema. The results suggest an inverse association between atopic diseases and colonization of the gut by probiotics.

Clinical implications

The prevention of atopic eczema in high-risk infants is possible by modulating the infant's gut microbiota with probiotics and prebiotics.

Key words: Allergy, prevention, probiotic, prebiotic, eczema, atopic eczema, high-risk infants, colonization

Abbreviations used: cfu, Colony-forming unit, OR, Odds ratio

 

 Supported by the Helsinki University Central Hospital Research Funds and Valio Ltd, Helsinki, Finland. Part-time monthly salaries that M.K. received and monthly salaries that K.K. received from the Clinical Research Institute Helsinki University Central Hospital Ltd were funded by Valio Ltd.Disclosure of potential conflict of interest: K. Kukkonen has received grant support from Valio Ltd. R. Korpela and T. Tuure are employed by Valio Ltd and by R&D. T. Poussa has consultant arrangements with Valio Ltd. M. Kuitunen has received grant support from Valio Ltd. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(06)01908-7

doi:10.1016/j.jaci.2006.09.009

The Journal of Allergy and Clinical Immunology
Volume 119, Issue 1 , Pages 192-198, January 2007